Skip to main content
Clinical Trials/NCT02308917
NCT02308917RecruitingNot Applicable

The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN): A Partnership With the CH.I.L.D. Foundation: Multi-center Inception Cohort Study

The Hospital for Sick Children12 sites in 1 country2,400 target enrollmentStarted: September 2013Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
2,400
Locations
12
Primary Endpoint
Sustained Clinical Remission

Study Overview

Brief Summary

The CIDsCaNN Network is being established with the major goals of identifying why IBD develops so commonly in children and adolescents living in Canada, and of determining the best treatment strategies for different types of IBD. Focusing on a prospective, inception cohort of Canadian children of widely varied racial origins provides a unique opportunity to explore environmental risk factors early in life and close in time to disease onset, their influence on the host microbiome, and in the context of genetic susceptibility. In keeping with current treatment targets, assessed outcomes will include not only symptom resolution and growth, but also intestinal healing. We aim to identify best practice and to institute processes for continual improvement in care nationally.

Detailed Description

IBD is also known as Crohn's Disease or Ulcerative Colitis. Please read the definitions of each of these conditions below:

  1. Crohn's Disease: A condition that causes "inflammation" which is swelling, redness, soreness, in different parts of your intestines; either the large intestine only, the small intestine only or both.
  2. Ulcerative Colitis: A condition that causes "inflammation" which is swelling, redness and soreness in the lining of your large intestine (colon) only.

IBD may run in families, meaning that it can be passed down through genes. However, compared to other parts of the world, it has been found that the number of children with IBD living in Canada is higher. It has also been found that children whose families have come from parts of the world where IBD is not common, have the same chance of developing IBD as children born and raised in Canada. This seems particularly true for children, whose families have come here from South Asia. Because of this, doctors think that aside from genetic factors, there may be factors in the environment to explain why this has been observed.

At this time, the factors in the environment which can trigger the development of IBD are not well understood. By working together in the Network, physicians who treat IBD will be able to gain a better understanding of the environmental factors that contribute to the development of IBD.

We aim to enroll children and teenagers who have developed IBD and are being treated at participating Network centers in Canada with the goal of sharing biological samples, demographic and lifestyle information, disease history, and treatment outcomes.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
2 Years to 17 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • diagnosed with IBD - Crohn's, ulcerative colitis or inflammatory bowel disease undefined

Exclusion Criteria

  • Refusal to give informed consent

Outcomes

Primary Outcomes

Sustained Clinical Remission

Time Frame: 18 months after enrollment onto study

Primary outcome: To test the research hypothesis, the primary endpoint is sustained clinical remission, as defined for CD by PCDAI \<10 and for UC as PUCAI \< 10 at each of the 6, 12, and 18 month visits AND physician global assessment of interval disease severity as quiescent at each of these visits. This primary endpoint will be assessed at 18 months, although it is the intent of the network to continue evaluations of the cohort until transfer to adult care.

Secondary Outcomes

  • Other Clinical Outcomes (combination of Pediatric Crohn's Disease Activity Index, Pediatric Ulcerative Colitis Activity Index, physician global assessment of disease activity, serologic inflammatory markers and fecal calprotectin results)(18 months after initial enrollment onto study)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Anne Griffiths

Division Head, Gastroenterology, Hepathology and Nutrition

The Hospital for Sick Children

Study Sites (12)

Loading locations...

Similar Trials

The Canadian Children Inflammatory Bowel... | Clinical Trial